<p>丹纳赫（NYSE:DHR - 获取免费报告）在周日发布的报告中被华尔街 Zen 的分析师从 “持有” 评级上调至 “买入” 评级。</p>
<ul>
<li>3 只提供强劲价值和稳定性的股票</li>
</ul>
<p>DHR 还受到其他几份报告的关注。瑞银集团将丹纳赫的目标价从 275.00 美元下调至 240.00 美元，并在 4 月 23 日的研究报告中给予该公司 “买入” 评级。古根海姆在 4 月 23 日的研究报告中重申了 “买入” 评级，并对丹纳赫的股票设定了 250.00 美元的目标价。巴克莱在 4 月 22 日的研究报告中将丹纳赫的目标价从 205.00 美元上调至 215.00 美元，并给予该股票 “超配” 评级。摩根大通在 4 月 22 日的研究报告中将丹纳赫的目标价从 280.00 美元下调至 260.00 美元，并为该公司设定了 “超配” 评级。最后，杰富瑞金融集团在 4 月 22 日的研究报告中将丹纳赫的目标价从 260.00 美元下调至 230.00 美元，并给予该公司 “买入” 评级。四位投资分析师对该股票给予了持有评级，十七位分析师对该公司的股票给予了买入评级。根据 MarketBeat 的数据，丹纳赫的平均评级为 “适度买入”，平均目标价为 263.24 美元。</p>
<p><strong>获取我们对丹纳赫的最新股票分析</strong></p>
<h2>丹纳赫股票下跌 0.5%</h2>
<ul>
<li>安捷伦科技受益于对永久性化学品的打击</li>
</ul>
<p>DHR 在周五开盘价为 189.54 美元。丹纳赫的 1 年低点为 171.00 美元，1 年高点为 281.70 美元。该公司的流动比率为 1.40，速动比率为 1.05，债务与股本比率为 0.31。该股票的市值为 1356.5 亿美元，市盈率为 35.90，市盈增长比率为 2.66，贝塔值为 0.80。该公司的 50 日移动平均线为 192.72 美元，200 日移动平均线为 213.59 美元。</p>
<p>丹纳赫（NYSE:DHR - 获取免费报告）最后一次发布季度财报是在 4 月 22 日，周二。该综合企业报告季度每股收益为 1.88 美元，超出市场共识预期的 1.62 美元，超出幅度为 0.26 美元。丹纳赫的股本回报率为 10.82%，净利润率为 16.33%。该公司在本季度的收入为 57.4 亿美元，而分析师预期为 55.8 亿美元。整体来看，卖方分析师预计丹纳赫在当前年度的每股收益将达到 7.63 美元。</p>
<h2>内部活动</h2>
<ul>
<li>丹纳赫股票在 2024 年会创下新高吗？</li>
</ul>
<p>在其他新闻中，董事长史蒂文·M·雷尔斯在 5 月 12 日（周一）出售了 125 万股公司的股票。该股票以平均 196.74 美元的价格出售，总价值为 245,925,000.00 美元。出售完成后，董事长现在直接持有 3105808 股公司股票，价值约为 611,036,665.92 美元。这笔交易代表了他们持股比例的 28.70% 的减少。该出售在向 SEC 的备案中披露，相关信息可通过此链接获取。此外，执行副总裁克里斯托弗·保罗·赖利在 4 月 30 日（周三）出售了 15805 股丹纳赫股票。该股票以平均 198.00 美元的价格出售，总价值为 3,129,390.00 美元。出售完成后，执行副总裁现在持有 15179 股公司股票，价值约为 3,005,442 美元。这笔交易代表了他们持股比例的 51.01% 的减少。该出售的披露信息可以在这里找到。目前，11.20% 的股票由公司内部人士持有。</p>
<h2>丹纳赫的机构交易</h2>
<p>一些对冲基金和其他机构投资者最近增加或减少了对该公司的持股。先锋集团在第一季度将其在丹纳赫的持股增加了 0.4%。先锋集团现在拥有 59,981,088 股该综合企业的股票，价值为 12,296,123,000 美元，此前在该期间内又购买了 230,966 股。T. Rowe Price Associates Inc. MD 在第一季度将其在丹纳赫的持股增加了 3.2%。T. Rowe Price Associates Inc. MD 现在拥有 19,592,211 股该综合企业的股票，价值为 4,016,404,000 美元，此前在该期间内又购买了 612,154 股。Geode Capital Management LLC 在第四季度将其在丹纳赫的持股增加了 2.4%。Geode Capital Management LLC 现在拥有 13,358,206 股该综合企业的股票，价值为 3,056,996,000 美元，此前在该期间内又购买了 315,446 股。挪威银行在第四季度获得了丹纳赫的新股份，价值约为 2,130,740,000 美元。最后，纽约梅隆银行在第一季度将其在丹纳赫的持股增加了 2.3%。纽约梅隆银行现在拥有 8,783,485 股该综合企业的股票，价值为 1,800,614,000 美元，此前在该期间内又购买了 194,466 股。目前，79.05% 的股票由机构投资者和对冲基金持有。</p>
<h2>丹纳赫公司简介</h2>
<p>（获取免费报告）</p>
<p>丹纳赫公司在全球范围内设计、制造和销售专业、医疗、工业和商业产品及服务。生物技术部门提供生物处理技术、耗材和服务，以推进、加速和整合治疗药物的开发和生产；细胞系和细胞培养基开发服务；用于制造的细胞培养基、工艺液体和缓冲液、色谱树脂、过滤技术、无菌灌装；一次性硬件和耗材及服务，如完整制造套件的设计和安装；实验室过滤、分离和纯化；实验室规模的蛋白质纯化和分析工具；试剂、膜和服务；以及医疗过滤解决方案。</p>
<h2>相关文章</h2>
<ul>
<li>我们更看好的五只股票而非丹纳赫</li>
<li>制造业股票投资</li>
<li>接近 52 周低点，这三只中型股值得关注</li>
<li>罗素 2000 指数，投资者如何利用它进行盈利交易</li>
<li>在动荡时期，三只被忽视的股息投资机会</li>
<li>三只国防股票将受益于军事支出增加</li>
<li>AXON：摩托罗拉以 44 亿美元收购，竞争加剧</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURIUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURIUg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在丹纳赫吗？</h2>
<p>在你考虑丹纳赫之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前立即购买的股票……而丹纳赫并不在名单上。</p>
<p>虽然丹纳赫目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

丹纳赫

<p>华尔街禅将丹纳赫（NYSE:DHR）的评级从 “持有” 上调至 “买入”。瑞银集团将其目标价从 275 美元下调至 240 美元，同时维持 “买入” 评级。古根海姆重申 “买入” 评级，目标价为 250 美元，巴克莱将目标价从 205 美元上调至 215 美元。丹纳赫的平均评级为 “适度买入”，目标价为 263.24 美元。该股票开盘价为 189.54 美元，1 年最低价为 171 美元，最高价为 281.70 美元。丹纳赫报告每股收益为 1.88 美元，超出预期，营收为 57.4 亿美元</p>

<p>Danaher (NYSE:DHR - Get Free Report) was upgraded by analysts at Wall Street Zen from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report issued on Sunday.</p>
<div class="lb-trans"><p>丹纳赫（NYSE:DHR - 获取免费报告）在周日发布的报告中被华尔街 Zen 的分析师从 “持有” 评级上调至 “买入” 评级。</p>
</div><ul>
<li>3 Stocks Offering Strong Value and Stability</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只提供强劲价值和稳定性的股票</li>
</ul>
</div><p>DHR has been the subject of several other reports. UBS Group reduced their target price on Danaher from $275.00 to $240.00 and set a &#34;buy&#34; rating for the company in a research report on Wednesday, April 23rd. Guggenheim reaffirmed a &#34;buy&#34; rating and issued a $250.00 target price on shares of Danaher in a research report on Wednesday, April 23rd. Barclays raised their target price on Danaher from $205.00 to $215.00 and gave the stock an &#34;overweight&#34; rating in a research report on Tuesday, April 22nd. JPMorgan Chase &amp; Co. reduced their target price on Danaher from $280.00 to $260.00 and set an &#34;overweight&#34; rating for the company in a research report on Tuesday, April 22nd. Finally, Jefferies Financial Group reduced their target price on Danaher from $260.00 to $230.00 and set a &#34;buy&#34; rating for the company in a research report on Tuesday, April 22nd. Four investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to MarketBeat, Danaher has an average rating of &#34;Moderate Buy&#34; and an average price target of $263.24.</p>
<div class="lb-trans"><p>DHR 还受到其他几份报告的关注。瑞银集团将丹纳赫的目标价从 275.00 美元下调至 240.00 美元，并在 4 月 23 日的研究报告中给予该公司 “买入” 评级。古根海姆在 4 月 23 日的研究报告中重申了 “买入” 评级，并对丹纳赫的股票设定了 250.00 美元的目标价。巴克莱在 4 月 22 日的研究报告中将丹纳赫的目标价从 205.00 美元上调至 215.00 美元，并给予该股票 “超配” 评级。摩根大通在 4 月 22 日的研究报告中将丹纳赫的目标价从 280.00 美元下调至 260.00 美元，并为该公司设定了 “超配” 评级。最后，杰富瑞金融集团在 4 月 22 日的研究报告中将丹纳赫的目标价从 260.00 美元下调至 230.00 美元，并给予该公司 “买入” 评级。四位投资分析师对该股票给予了持有评级，十七位分析师对该公司的股票给予了买入评级。根据 MarketBeat 的数据，丹纳赫的平均评级为 “适度买入”，平均目标价为 263.24 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on Danaher</strong></p>
<div class="lb-trans"><p><strong>获取我们对丹纳赫的最新股票分析</strong></p>
</div><h2>Danaher Stock Down 0.5%</h2>
<div class="lb-trans"><h2>丹纳赫股票下跌 0.5%</h2>
</div><ul>
<li>Agilent Technologies Thrives From the Forever Chemicals Crackdown</li>
</ul>
<div class="lb-trans"><ul>
<li>安捷伦科技受益于对永久性化学品的打击</li>
</ul>
</div><p>DHR opened at $189.54 on Friday. Danaher has a 1-year low of $171.00 and a 1-year high of $281.70. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $135.65 billion, a price-to-earnings ratio of 35.90, a P/E/G ratio of 2.66 and a beta of 0.80. The business has a 50 day moving average of $192.72 and a 200-day moving average of $213.59.</p>
<div class="lb-trans"><p>DHR 在周五开盘价为 189.54 美元。丹纳赫的 1 年低点为 171.00 美元，1 年高点为 281.70 美元。该公司的流动比率为 1.40，速动比率为 1.05，债务与股本比率为 0.31。该股票的市值为 1356.5 亿美元，市盈率为 35.90，市盈增长比率为 2.66，贝塔值为 0.80。该公司的 50 日移动平均线为 192.72 美元，200 日移动平均线为 213.59 美元。</p>
</div><p>Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.26. Danaher had a return on equity of 10.82% and a net margin of 16.33%. The company had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. As a group, sell-side analysts anticipate that Danaher will post 7.63 earnings per share for the current year.</p>
<div class="lb-trans"><p>丹纳赫（NYSE:DHR - 获取免费报告）最后一次发布季度财报是在 4 月 22 日，周二。该综合企业报告季度每股收益为 1.88 美元，超出市场共识预期的 1.62 美元，超出幅度为 0.26 美元。丹纳赫的股本回报率为 10.82%，净利润率为 16.33%。该公司在本季度的收入为 57.4 亿美元，而分析师预期为 55.8 亿美元。整体来看，卖方分析师预计丹纳赫在当前年度的每股收益将达到 7.63 美元。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><ul>
<li>Will Danaher stock hit new highs in 2024?</li>
</ul>
<div class="lb-trans"><ul>
<li>丹纳赫股票在 2024 年会创下新高吗？</li>
</ul>
</div><p>In other news, Chairman Steven M. Rales sold 1,250,000 shares of the firm's stock in a transaction on Monday, May 12th. The stock was sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the sale, the chairman now directly owns 3,105,808 shares in the company, valued at approximately $611,036,665.92. This trade represents a 28.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the sale, the executive vice president now owns 15,179 shares of the company's stock, valued at approximately $3,005,442. The trade was a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.20% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新闻中，董事长史蒂文·M·雷尔斯在 5 月 12 日（周一）出售了 125 万股公司的股票。该股票以平均 196.74 美元的价格出售，总价值为 245,925,000.00 美元。出售完成后，董事长现在直接持有 3105808 股公司股票，价值约为 611,036,665.92 美元。这笔交易代表了他们持股比例的 28.70% 的减少。该出售在向 SEC 的备案中披露，相关信息可通过此链接获取。此外，执行副总裁克里斯托弗·保罗·赖利在 4 月 30 日（周三）出售了 15805 股丹纳赫股票。该股票以平均 198.00 美元的价格出售，总价值为 3,129,390.00 美元。出售完成后，执行副总裁现在持有 15179 股公司股票，价值约为 3,005,442 美元。这笔交易代表了他们持股比例的 51.01% 的减少。该出售的披露信息可以在这里找到。目前，11.20% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Trading of Danaher</h2>
<div class="lb-trans"><h2>丹纳赫的机构交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in Danaher by 0.4% in the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate's stock worth $12,296,123,000 after purchasing an additional 230,966 shares during the period. Price T Rowe Associates Inc. MD increased its position in Danaher by 3.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate's stock worth $4,016,404,000 after purchasing an additional 612,154 shares during the period. Geode Capital Management LLC increased its position in Danaher by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 13,358,206 shares of the conglomerate's stock worth $3,056,996,000 after purchasing an additional 315,446 shares during the period. Norges Bank acquired a new stake in Danaher in the fourth quarter worth about $2,130,740,000. Finally, Bank of New York Mellon Corp increased its position in Danaher by 2.3% in the first quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock worth $1,800,614,000 after purchasing an additional 194,466 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近增加或减少了对该公司的持股。先锋集团在第一季度将其在丹纳赫的持股增加了 0.4%。先锋集团现在拥有 59,981,088 股该综合企业的股票，价值为 12,296,123,000 美元，此前在该期间内又购买了 230,966 股。T. Rowe Price Associates Inc. MD 在第一季度将其在丹纳赫的持股增加了 3.2%。T. Rowe Price Associates Inc. MD 现在拥有 19,592,211 股该综合企业的股票，价值为 4,016,404,000 美元，此前在该期间内又购买了 612,154 股。Geode Capital Management LLC 在第四季度将其在丹纳赫的持股增加了 2.4%。Geode Capital Management LLC 现在拥有 13,358,206 股该综合企业的股票，价值为 3,056,996,000 美元，此前在该期间内又购买了 315,446 股。挪威银行在第四季度获得了丹纳赫的新股份，价值约为 2,130,740,000 美元。最后，纽约梅隆银行在第一季度将其在丹纳赫的持股增加了 2.3%。纽约梅隆银行现在拥有 8,783,485 股该综合企业的股票，价值为 1,800,614,000 美元，此前在该期间内又购买了 194,466 股。目前，79.05% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Danaher Company Profile</h2>
<div class="lb-trans"><h2>丹纳赫公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.</p>
<div class="lb-trans"><p>丹纳赫公司在全球范围内设计、制造和销售专业、医疗、工业和商业产品及服务。生物技术部门提供生物处理技术、耗材和服务，以推进、加速和整合治疗药物的开发和生产；细胞系和细胞培养基开发服务；用于制造的细胞培养基、工艺液体和缓冲液、色谱树脂、过滤技术、无菌灌装；一次性硬件和耗材及服务，如完整制造套件的设计和安装；实验室过滤、分离和纯化；实验室规模的蛋白质纯化和分析工具；试剂、膜和服务；以及医疗过滤解决方案。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相关文章</h2>
</div><ul>
<li>Five stocks we like better than Danaher</li>
<li>Manufacturing Stocks Investing</li>
<li>Near 52-Week Lows, These 3 Mid-Cap Stocks Are Worth a Look</li>
<li>Russell 2000 Index, How Investors Use it For Profitable Trading</li>
<li>3 Overlooked Dividend Plays for Income in Volatile Times</li>
<li>3 Defense Stocks Set to Benefit From Increased Military Spending</li>
<li>AXON: Competition Intensifies as Motorola Makes $4.4B Acquisition</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票而非丹纳赫</li>
<li>制造业股票投资</li>
<li>接近 52 周低点，这三只中型股值得关注</li>
<li>罗素 2000 指数，投资者如何利用它进行盈利交易</li>
<li>在动荡时期，三只被忽视的股息投资机会</li>
<li>三只国防股票将受益于军事支出增加</li>
<li>AXON：摩托罗拉以 44 亿美元收购，竞争加剧</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPURIUg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=DHR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Danaher Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在丹纳赫吗？</h2>
</div><p>Before you consider Danaher, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑丹纳赫之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛市场注意到之前立即购买的股票……而丹纳赫并不在名单上。</p>
</div><p>While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然丹纳赫目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

丹纳赫（NYSE:DHR）的评级在 Wall Street Zen 被提升至买入